1 / 20

British Association of Dermatologists’ Biologic Intervention Register (BADBIR) Update November 2007

British Association of Dermatologists’ Biologic Intervention Register (BADBIR) Update November 2007. Aim of the Register. To investigate the long-term outcome of psoriasis patients treated with biologic agents, with particular reference to safety Primary endpoints of interest

megan
Download Presentation

British Association of Dermatologists’ Biologic Intervention Register (BADBIR) Update November 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. British Association of Dermatologists’ Biologic Intervention Register (BADBIR)Update November 2007

  2. Aim of the Register • To investigate the long-term outcome of psoriasis patients treated with biologic agents, with particular reference to safety • Primary endpoints of interest • anymalignancy • any infection requiring hospitalisation • serious adverse events • death

  3. Subsidiary Aims • Long-term effectiveness data • Evaluate differences in effectiveness between agents • Assess whether sequential therapy with multiple biologic agents acts synergistically to increase the risk • Assess whether sequential therapy with conventional systemic anti-psoriatic therapy and biologic agents acts synergistically to increase the risk

  4. Study Design • Prospective observational cohort study • 5 years active follow-up • Compare rates of events in 2 cohorts of psoriasis patients

  5. Eligibility Criteria • Age ≥ 16years • Severe psoriasis(definition: PASI ≥10 and DLQI >10) • Informed consent • Under care of a UK dermatologist Recommendation from BAD and NICE All patients treated with biologic agents be registered with BADBIR

  6. Observational study vs Biologic Cohort Conventional cohort (anti-psoriatic therapy) • Commencing biologic therapy in last 6 months • infliximab • etanercept • efalizumab • Starting or switching conventional anti-psoriatic therapy • PUVA • MTX • ciclosporin • acitretin • fumaric acid esters • Biologic naïve

  7. Sample Size • Power to detect a 3-4 fold increase in skin cancer • Baseline risk in psoriasis • Non melanoma skin cancer = 100/100,000pyrs • Accounting for losses to follow-up and deaths, requires: Biologics: N = 4000 (per drug) N = 4000 Controls:

  8. Pharmocovigilance (1) Scientific epidemiological study (2) Regulatory authority purposes (on behalf of the companies) • Reporting/monitoring SAE data at specified time points

  9. Follow-up Methods 6 Monthly Annually Dermatology Team questionnaire 5 YEARS Annually 6 Monthly Patient questionnaire & diary 3 YEARS Office for National Statistics (ONS) flagging LIFE LONG Year 0 Year 3 Year 5

  10. Dermatology Team diagnosis and disease characteristics PASI DLQI EuroQol CAGE HAQ (if co-existing inflammatory arthritis) previous & current therapies co-morbidities Patient Demographics occupational status smoking history Data collected at baseline

  11. Dermatology team changes in therapy adverse event information pathology/microbiology reports current PASI Patient DLQI EuroQol ?HAQ 6 monthly diary any hospitalisation any new drugs any referrals Data collected at follow up

  12. Time contributed to comparison cohort Time contributed to biologic cohort Drug 0 6 12 18 24 30 36 Time (months) Switching between cohorts Anti-psoriatic therapy Biologic therapy

  13. Data Collection • Dermatology Team – web based transfer • Patient – paper based questionnaires • Website: www.badbir.org

  14. Website(under construction) www.badbir.org

  15. BADBIR database security model

  16. Funding • To help towards time spent collecting this data • The following payment plan is planned • Fully completed baseline form: £100 • Fully completed follow–up form: £50 • (total of 8 follow-up forms over five years) 

  17. Location of Pilot Centres • Seven centres • All have LREC approval • 5 have R & D approval • 25 patients have been registered in the pilot phase

  18. Procedure for gaining ethical approvalsPrincipal Investigator – Consultant Dermatologist

  19. If you are interested in becoming involved Contact Dr Kathy McElhone BADBIR Study Co-ordinator Telephone: 0161 603 7731 Email: kathleen.mcelhone@manchester.ac.uk

  20. In conclusion: BADBIR • Will help to answer important questions about long term safety of both biologic and systemic anti-psoriatic therapy • Enable us to provide more accurate, better quality information to patients commencing on both the biologic and the conventional treatments • Importance of Nurses involvement • Identified as key to the management of patients on biologic therapy

More Related